Alzheimer's disease is the most prevalent neurodegenerative disease among elderly and a 2 major burden to society (Prince et al., 2013; Wimo et al., 2013) . AD patients are 3 characterized by progressive cognitive decline, that starts with mild cognitive impairments 4 (MCI) and develops over time in full blown dementia. The brains of AD patients are 5 characterized by the abundant presence of amyloid plaques, that are located extracellularly 6 and contain various β-amyloid (Aβ) peptides, and by neurofibrillary tangles that are made up 7 of hyper-phosphorylated tau inside of neurons (Querfurth and LaFerla, 2010; Scheltens et 8 al., 2016) . Neurodegeneration in the hippocampus, as the results of these neuropathological 9
changes, is one of the key features of AD and in concert to the hippocampus other brain 10 regions involved in the medial temporal lobe memory circuit are affected too (Weiner et al., 11 2015) . 12
A small percentage of the demented population suffers from familial AD, in which the 13 disease results from genetic mutations and/or specific gene variants. For the majority of 14 patients with sporadic, late-onset AD, however, no genetic or heritable causes have been 15
identified. These patients have been reported to show a high degree of heterogeneity in the 16 progress of clinical symptoms, hippocampal plasticity and neuropathological characteristics 17 Interestingly, ES triggered Aβ formation in non-transgenic rats; MS from P2 to P21 1 induced an elevated ratio of the amyloid precursor protein (APP)-derived fragments C99 and 2 C83, and an increased expression of Aβ40 and Aβ42 peptides in the hippocampus of adult 3 (Martisova et al., 2012; 2013; Solas et al., 2010; 2013) and aged rats (Solas et al., 2010) . 4
While it is interesting to learn that ES enhances amyloidogenic processing in the brain of wild 5 type rodents, these rats do not develop the pathological oligomeric or fibril forms of Aβ. ES 6 experiments performed in transgenic AD models that do express these pathological Aβ 7 species help to uncover if ES advances or accelerates these specific features of AD pathology 8 with age. 9
Perinatal stress was shown to affect the later development of amyloid 10 neuropathology in transgenic AD models in an age-and thus intrinsically pathological stage-11 dependent manner. In fact, both prenatal maternal-restraint stress (PS) from embryonic day 12 (E)1 to E7 as well as chronic ES from postnatal day (P)2-P9 reduced Aβ in the hippocampus of 13 4-month-old APPswe/PS1dE9 mice, a relatively early pathological stage. Specifically, Aβ 14 plaque load in the hippocampus of female, but not male, APPswe/PS1dE9 mice was 15 decreased after PS, while no effects were found on intracellular Aβ immunoreactivity, nor on 16 hippocampal soluble Aβ40 and Aβ42 peptide levels (Sierksma et al., 2012; 2013) . Chronic ES 17 from P2 to P9 also reduced intraneuronal Aβ levels in the dentate gyrus of male 18
APPswe/PS1dE9 mice (Hoeijmakers et al., 2017) . On the other hand, 4-month-old bigenic 19 (BiAT) mice, which express both amyloid and tau mutant genes, exposed to the same chronic 20 ES design showed an elevation of Aβ peptide levels (Lesuis et al., 2016) . Interestingly, at a 21 later pathological stage in 9-and 10-month-old APPswe/PS1dE9 mice, hippocampal plaque 22 load was aggravated after exposure to chronic ES from P2-P9 or after 3 weeks of MS 23 (Hoeijmakers et al., 2017; Hui et al., 2017), while cortical plaque load was affected by MS at 24 this age as well (Hui et al., 2017) . This shows that although in some models Aβ is initially 25 reduced in young adulthood, the pathology is exacerbated by ES exposure at later ages . 26 In contrast to the modulation of Aβ peptides, tau pathology received very little 27 attention in ES studies so far. Interestingly, tau protein in the hippocampus undergoes 28 specific isoform switches and phosphorylation changes during the early-life period, which 29
have been suggested to contribute to neuronal development and function (Sennvik et al., Interestingly, ES exposure also seemed to affect the cognitive performance of 3
APPswe/PS1dE9 mice. The reduced Aβ plaque load in PS-exposed APPswe/PS1dE9 mice at 4 4 months and the MS-induced increased Aβ plaque load in the same transgenic mice at 9 5 months were associated with, respectively, improved and impaired performance in 6 hippocampus-dependent cognitive tasks (Hui et al., 2017; Sierksma et al., 2013) . Such ES-7 induced cognitive modulation was not detected in 4-month-old BiAT mice as both control 8 and ES-exposed BiAT mice were unimpaired at this age (Lesuis et al., 2016). 9
In contrast to ES, and in support of the important role for the (quality of the) early-10 life environment, a 'positive' early-life experience attenuated Aβ pathology and cognitive 11 decline. For instance, early handling (EH) from P2 to P9, which was associated with improved 12 care by the mother, reduced Aβ levels in 4-month-old BiAT mice and in 11-month-old 13
APPswe/PS1dE9 mice (Lesuis et al., 2016; 2017) . This reduction in amyloid levels in 14
APPswe/PS1dE9 mice after EH was further accompanied by an improved cognitive 15 performance at 11 months of age (Lesuis et al., 2017). In addition, prolonged EH exposure 16 from P1-P21 prevented spatial learning impairments at a pre-pathological stage, in 4-month-17 old male and female 3xTgAD mice (Cañete et al., 2015) . 18
These initial studies strongly suggest that perinatal experiences can shape the later 19 progression of Aβ neuropathology and cognitive performance. In general, it appears as if 20 stress experienced in early-life reduces Aβ pathological hallmarks at an early pathological 21 stage, while it ultimately aggravates Aβ pathology at more advanced pathological stages. 22
These alterations are associated with parallel changes in cognition. So far, these conclusions 23 are based on only a few studies, which focus on Aβ rather than on tau neuropathology. This 24 highlights the need to extend our knowledge of the consequences of ES at different 25 pathological stages. Moreover, with the exception of the EH study in APPswe/PS1dE9 mice 26 (Lesuis et al., 2017), these studies addressed cognition only in transgenic mice and not in 27 age-matched wild type mice exposed to the early-life paradigm (Cañete et al., 2015 , Hui et 28 al., 2017 Sierksma et al., 2013) . The inclusion of these control groups would be relevant in 29 order to assess whether AD pathology accelerates or aggravates the onset of cognitive 30
impairments relative to unstressed transgenic as well as stressed wild type groups. It is also 31 important to understand which mechanisms are involved and which pathways might 32 mediate such late consequences. This is addressed in the following sections.
Stress in early-life modulates regulators of Aβ and tau neuropathological progression 1
So far, most of the aforementioned ES studies have not fully addressed the possible 2 mechanisms mediating the later neuropathological changes. It is interesting to speculate 3 whether mechanisms involved in the effects of adult stress on AD neuropathology might also 4 be important to consider in the context of early-life experiences. In fact, the impact of adult 5 stress exposure on Aβ and tau hallmarks has been more extensively studied in various AD 6 models (Machado et al., 2014; Marcello et al., 2015) . 7
Overall, there are several pathways in which stress exposure can regulate Aβ 8 progression. These include; 1) driving Aβ synthesis via the modulation of APP expression and 9
the APP-cleaving secretases, or 2) by modulating clearance of Aβ, for instance by changes in 10 transportation to the periphery or by altering the rate of phagocytosis by immune cells 11 propagation of tau neuropathology on the other hand, is similarly modulated by tau 13 expression, tau mutations, and activity of specific kinases and phosphatases. These factors 14 are driving tau neuropathology and also 'prion-like' tau propagation is of relevance in this 15 respect (Sanders et al, 2014) . Alternatively, tau can be cleared through degradation 16 pathways, halting the progression of pathology. We will here discuss the existing literature 17 on these proposed regulators of AD neuropathology following (early-life) stress exposure. 18 19
Stress-related factors modulate AD neuropathology 20
Stress-related factors are certainly important to consider as possible modulators of AD 21 pathology. Not only were stress hormone levels shown to be dysregulated in AD patients 22 to be mediated by stress-related hormones and neuropeptides, such as glucocorticoids 26
(cortisol in human and corticosterone in rodents) and corticotropin releasing hormone/ 27 factor (CRH; CRF). Interestingly, ES exposure has been described to alter later hypothalamic 28 pituitary adrenal (HPA) axis functioning, leading to an increased responsiveness to stressors 29 and overexposing body and brain to elevated levels of glucocorticoids (reviewed in Frodl and As an example, glucocorticoid exposure and chronic stress in wild type rats enhanced 9 phosphorylation of tau protein in the hippocampus and prefrontal cortex, likely through the 10 elevated expression of kinases, and these alterations were associated with cognitive deficits 11 in the rats (Sotiropoulos et al., 2011) . Tau knockout mice further showed resilience for (part 12 of) the stress-induced hippocampal abnormalities and cognitive deficits (Lopes et al., 2016), 13
indicating a mechanism through which stress-induced tau alterations can enhance 14 neuropathological hallmarks as well as vulnerability for cognitive deficits. 15
With respect to Aβ pathology, the expression of APP and the APP cleaving enzyme β-16 secretase 1 (BACE1) was increased by exposure to corticosterone or to the glucocorticoid 17 receptor (GR) agonist dexamethasone, both in neuronal cell cultures as well as in 3xTgAD 18 mice. These changes increased expression of APP-derived fragments (C99, C83), and notably, 19 they further steered APP processing towards the amyloidogenic pathway, ultimately that arises directly after ES exposure and lasts into adulthood, and it will be interesting to 10 study whether this or an ES-mediated rise in glucocorticoid levels and subsequent GR 11 activation in adulthood affected methylation and the eventual BACE1 expression pattern. 12
Chronic ES exposure did not induce an increase in basal corticosterone in adult mice 13 (Naninck et al., 2015; 2017) and, thus, not all ES models induce elevated basal or stress-14 induced corticosterone levels. Whether glucocorticoid levels in chronic ES-exposed mice 15 affect BACE1 expression, APP or other factors in the amyloid processing pathway to mediate 16 the increased Aβ pathology in APPswe/PS1dE9 mice remains thus to be determined. In contrast to these observations, multiple studies have indicated that stress Next to this, several studies have also attributed the potential of stress to enhance To summarize the role of (early-life) stress-related factors in the later vulnerability to 21 develop AD, both glucocorticoids and CRF have been implicated in the progression of AD 22
neuropathology. This supports the possibility that the enhanced AD vulnerability after ES 23 might be mediated by the alterations in the stress system. Intervention studies that 24 modulate the consequences of ES on stress signaling should help to clarify these cause-or-25 effect aspects and further elucidate this relationship. In addition, it will be interesting to 26
investigate if ES has the potential to also (epigenetically) program expression of AD 27 neuropathological modulators, such as tau, APP, or BACE1 expression, possibly via GR 28 activation. 29 
Regulation of the inflammatory response to amyloid neuropathology by ES 31
Over the recent years, attention for the role of neuroinflammation in AD etiology has 32 One can speculate that the changes in neuropathology between 4 (reduced Aβ in ES 21 group) and 10 months (increased Aβ in ES group) in the ES-exposed mice were not due to 22 differences in Aβ production, but may rather result from a differential clearance mediated 23 through microglia. An outstanding question in that respect is, whether the microglial 24 response to inflammatory challenges like Aβ is intrinsically (epigenetically) programmed by 25 ES in the microglia, and then evoked by Aβ exposure in adulthood. Other ES studies in rats 26 have indeed shown that the microglial response in adulthood was primed or sensitized when 27 stimulated by secondary inflammatory challenges, leading to an enhance (pro-)inflammatory other cell types, such as neurons and astrocytes, release factors that can regulate microglia 30 and thereby modulate their inflammatory response. As an example, fractalkine signaling 31 between neurons and microglia was found to be diminished in PS-exposed rats by the Together, these data show that ES affects microglia and their neuroinflammatory 4 responses, and that this in turn might modulate Aβ neuropathological progression. It still 5 needs to be elucidated if an altered microglial phenotype after ES exposure might contribute 6
to aggravated Aβ pathology in APPswe/PS1dE9 mice via a change in Aβ clearance. In 7 addition, it will be important to further investigate if the microglial phenotype in ES 8
APPswe/PS1dE9 mice results from an intrinsic, primed, or sensitized microglial response to 9
Aβ. Alternatively, the Aβ accumulating in ES-exposed mice might have elicited impairments 10 in other cell types in the brain, which may then stimulate the microglia to respond more or 11 less strongly. 12 13
Metabolic factors can play a role in progression of AD neuropathology after ES 14
Other factors that can modulate AD vulnerability after ES exposure relate to the metabolic 15 
Insulin resistance in AD 2
Hyperinsulinemia leads to a deficiency in insulin signaling, or insulin resistance, that can 3 ultimately develop into type II diabetes. Type II diabetes is highly prevalent world-wide and a 4 well-recognized risk factor that potentiates AD progression ( is thus consistent with the concept that ES increases the risk for hyperinsulinemia and insulin 26 resistance. Altogether, there is evidence for insulin-mediated AD hallmarks after ES 27 exposure, but additional investigation to directly tackle the effect of ES-modulated insulin 28 signaling in transgenic AD models are needed to gain insight into this topic. 29 , 2006) . This makes these poly-2 unsaturated fatty acid levels another interesting factor with respect to AD vulnerability. 3
Interestingly, ES reduced omega-3 fatty acids in the plasma of adult rats exposed to MS 4 during early-life (Clarke et al., 2009). In addition, when MS-exposed rats were fed an omega-5 3 deficient diet throughout adulthood, these rats showed a higher vulnerability for 6 metabolic deficits when compared to unstressed rats fed with this deficient diet (Bernardi et 7 al., 2013; Mathieu et al., 2008) . 8
These studies thus suggest that the reduction in omega-3 fatty acids after ES can 9 make ES-exposed mice more vulnerable to (progression of) AD neuropathology and 10 cognitive decline. But how can fatty acids exert such modulatory effects on the brain? 11
Dietary enrichment with omega-3 in adult unstressed mice showed that Aβ neuropathology 
Interplay of the neuropathological regulators that are affected by ES 26
As discussed in the previous sections, AD might progress after ES exposure through the 27 modulation of stress-related, neuroinflammatory and metabolic factors. Additional studies 28 on the direct consequences of ES for each of these modulating pathways, at different time 29 points in transgenic models of AD, should help to elucidate the determining factors. It must 30 be noted in this respect that the different systems that can affect AD neuropathology after 31 M A N U S C R I P T
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To further illustrate this subtle interplay between stress, neuroinflammation and 1 metabolism, hyperinsulinemia was for instance found to enhance central inflammation and it also difficult to tease out whether ES determines AD vulnerability through one common 18 denominator or driving factor, or whether a synergistic action of all these pathways is 19
involved. This awaits future studies. 20 21
AD vulnerability through ES-modulated neuroplasticity 22
Neuronal networks can be modified by selective pruning of synapses, formation of new, or 23 impairments in neuroplasticity are thought to underlie the cognitive deficits in ES-exposed 9 adults, and these neuroplasticity forms as well as cognition decline with aging (Barnes et al., 10 1997; Foster, 2012; Lindner, 1997). Considering this, we first discuss how ES intrinsically 11 affects such aging-related alterations in cognition and neuroplasticity in wild type rodents, 12
followed by the evidence for neuroplasticity alterations in AD models after ES exposure. 13 In aged rodents, cognitive impairments were exacerbated in PS-exposed rats (Vallee 3 et al., 1999) , and a similar phenotype was confirmed in aged rats that underwent MS from 4 P2-14 (Sousa et al., 2014) or from P2-P21 (Solas et al., 2010) . In comparison to age-matched 5 control rats, MD on P3 similarly led to a more cognitively impaired aged rats, but in addition 6
it also led to more good performers during the learning task (Oitzl et al., 2000) . This study 7 thus indicated that ES did not impair all rats, but rather that the individual variation within 8 the group was enhanced with aging after stress exposure early in life. 9
Altogether, the majority of these studies point to an aggravated age-related cognitive 10 decline in ES-exposed rodents. Such impairments in cognitive performance were 11 accompanied by impaired long-term potentiation in CA1-CA3 synapses of 16-month-old MS-12 exposed rats, when compared to age-matched controls (Sousa et al., 2014). A study of 30-to 13 32-month-old rats that were exposed to MD on P3 and classified as cognitively impaired or 14 unimpaired, based on Morris water maze training in aging, revealed that 5-HT receptor 1 15 mRNA expression in the hippocampus was more strongly increased in impaired MD rats 16 compared to the impaired control rats (Sibug et al., 2001 ). In addition, activity-regulated 17 cytoskeleton-associated protein (ARC) mRNA expression, but not brain-derived neurotrophic 18 factor (BDNF), was strongly reduced in aged rats with a history of MS, relative to unstressed 19 aged rats and adult groups (Solas et al., 2013) . 20
Other parameters of neuronal plasticity have, to our knowledge, so far not been 21 studied in aged ES-exposed rodents and their age-matched controls. Nevertheless, based on 22 the evidence for impaired cognitive performance of ES aged rats, it is to be expected that 23
neuronal plasticity parameters will be impaired too. Additional studies are needed to further 24 elucidate which factors are involved in the aggravated aging-related decline after ES. 25 26
ES might aggravate AD-related impairments in neuroplasticity 27
Next to a potential steeper decline with aging per se, it is plausible that ES exacerbates 28 various neuroplasticity hallmarks in AD transgenic mouse lines. For example, dendritic were performed in 4-month-old mice, an age when no cognitive deficits are yet present. It 1 will therefore be of particular interest to study the alterations in neuroplasticity also at an 2 age when cognitive functioning of ES transgenic mice differs from control transgenic mice, 3 such as for 9-month-old ES APPswe/PS1dE9. Interestingly, these 9-month-old ES-exposed 4
APPswe/PS1dE9 mice showed an increased loss of cholinergic neurons in their forebrain, in 5 close association with memory deficits (Hui et al., 2017) . These 3 studies together indicate 6 that neuroplasticity appears to be reduced by ES in AD transgenic mouse models. 7
Unfortunately, all 3 studies failed to include wild type littermates that are exposed to 8 the same early-life paradigms. This hampers the possibility to address whether the ES 9
phenotype is different or aggravated in mice with a transgenic background. Previous studies 10 subjecting wild type mice to the same stress paradigms showed that at least prefrontal by adult stress exposure in wild type mice, but more strongly so in the 3xTgAD mice 20 (Baglietto-Vargas et al., 2015) . When compared to wild type and control 3xTgAD mice, 6-21 month-old stress-exposed 3xTgAD mice additionally exhibited a stronger decrease in long-22 term potentiation, as was recorded in the CA1 stratum radiatium (Grigoryan et al., 2014) . 23
These studies suggest that adult stress can modulate neuroplasticity factors that in turn may 24 accelerate impairments, either as a result of a faster progression of neuropathology, or by 25 direct effects of adult stress regulation and stress hormone exposure on neuronal 26
functioning. 27
To conclude, neuroplasticity seems to be impaired in ES-exposed AD transgenic mice 28 compared to non-stressed transgenic mice. Such impairment appears in line with the 29 stronger cognitive decline in ES-exposed AD transgenic mice, however, it remains unclear 30 whether this impairment is similar for ES wild type and ES AD transgenic mice, or whether 31 the neuroplasticity impairments are stronger in the transgenic models exposed to ES. To 32 address this question, it is essential that future studies include both ES-exposed transgenic this way be the first step to comorbidity as a cumulative factor increasing vulnerability for 23
AD. 24
Given these later-life risk factors and the reduced cognitive functioning of ES-exposed 25 individuals, it can be questioned whether also the 'cognitive reserve' of ES-exposed 26 individuals is lower. Cognitive reserve can be seen as someone's ability to cope with 27 emerging damage in the brain, until a certain threshold is reached and the loss of function 28 becomes apparent (Stern, 2002) . Also in AD patients, neuropathological hallmarks have been 29 accumulating in the brain for many decades before the first clinical signs of AD arise as the indicating that childhood cognition may indeed be associated with cognition during aging. 5
However, the decline of these non-demented elderly between age 79 and 83 was not cognitive abilities specifically with an increased risk for (vascular) dementia, and not AD, 10 although the number of AD patients in these studies was very low. On a similar note, a 11 higher social economic household was associated with higher cognitive abilities that were 12 retained during aging, but neither higher nor lower social economic household were an 13 indicator for AD development (Wilson et al., 2005) . Transgenerational effects of (early-life) stress might in such a way lead to higher risk for 23 dementia in a heritable fashion. 24
Overall, the discussed studies show that childhood cognition is intrinsically associated 25 with specific forms of dementia, while cognitive abilities in adulthood were specifically 26 associated with a risk for AD. It will be of interest to further explore how general cognitive 27 abilities throughout life determine AD risk and whether indeed a lower cognitive reserve will 28 lead to an earlier onset of MCI and AD. 29 30
Mediators of ES vulnerability for AD; a model 31
The ES phenotype is suggested to be determined by the interplay of different systems M A N U S C R I P T
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ACCEPTED MANUSCRIPT 23 following model of ES-mediated vulnerability for AD ( figure 1 ). We hypothesize that ES 1 modulates the inflammatory, stress and/or metabolic systems. The interplay of these 2 systems will lead to aggravated AD-related neuropathology, which in turn can reduce 3 hallmarks of neuroplasticity, such as synaptic connectivity and hippocampal neurogenesis, to 4 ultimately diminished cognitive abilities. Alternatively, ES directly reduces neuroplasticity 5 and its associated cognitive functions through inflammatory, stress and metabolic regulation 6 as well, and may thereby potentially lower the cognitive reserve of ES individuals. Finally, ES 7
is an important risk factor for the occurrence of later-life stress events and such cumulative 8 stress again would induce a cumulative risk for deficits through the aforementioned 9 pathways. The studies on rodent models support a modulatory effect of stress experienced in early-life 16
in the progression of AD. Preclinical research has, however, not fully explored which factors 17 are involved in this relation, and more controlled preclinical studies are thus essential to 18 identify these factors, to unravel their interactions and to verify the current findings (Box 3). 19
Such knowledge, supported by (prospective) clinical studies, will strongly benefit the 20 identification of populations at elevated risk for AD, which can possibly allow to develop an 21 early and targeted treatment during the many decades between ES exposure and AD 22 
